By blocking IL-22 in keratinocytes, temtokibart normalizes the skin barrier and boosts hydration, suggested a study of gene expression changes in the skin.
Temtokibart, a novel monoclonal antibody, appears to achieve clinical improvements in moderate to severe atopic dermatitis by normalizing the skin barrier and increasing hydration, according to the results of a small, 16-week,Interleukin -22 expression is increased in AD and is thought to contribute to epidermal hyperplasia and impaired barrier integrity.
To investigate the mechanisms underlying that effect, researchers randomized 12 individuals with moderate to severe AD to temtokibart or IL-4R-alpha blocker dupilumab , every 2 weeks for 16 weeks. At baseline, the mean Eczema Area and Severity Index score was > 30 in the two arms, and > 75% patients were rated as having severe disease on the Validated Investigator Global Assessment scale for AD. The mean score on the Itch Numeric Rating Scale was approximately 7.
Skin punch biopsies and tape strips were taken at baseline and at 1, 4, and 16 weeks, and patients were followed up for another 16 weeks.As expected, both groups showed comparable, clinically relevant improvements in EASI and NRS itch scores at 16 weeks; no patients experienced serious or severe adverse events.gene expression. This was not seen with dupilumab, which showed a decrease in type 2–associated inflammatory markers, particularly in immune cells and fibroblasts.
Atopic Dermatitis Atopic Eczema Eczema Pruritus Pruritis Itch Anaplastic Lymphoma Kinase ALK ALK Tyrosine Kinase Receptor CD246 Cluster Of Differentiation 246 Punch Biopsy Biologic Therapy Biologics Adhesion Alpha Blockers Alpha-Blockers Alpha-Adrenergic-Antagonists Alpha Adrenergic Antagonists Biopsy Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Investigational mpox mRNA vaccine reduces disease severity in primates compared to available vaccinesThe most frequently used mpox vaccine provides partial immunity to the disease but isn't always able to prevent severe symptoms or disease transmission.
Read more »
FDA Approves Lebrikizumab for Atopic DermatitisMore than 1000 people age 12 years and older were enrolled in pivotal trials of the IL-13 inhibitor.
Read more »
Roflumilast Cream 0.15% Improves Atopic Dermatitis Symptoms in Phase 3 StudiesTreatment with roflumilast cream 0.15% once daily improved mild to moderate AD in two phase 3 randomized clinical trials of children 6 years or older and adults.
Read more »
Investigational Med for Tourette Syndrome PromisingPositive findings on co-occurring psychiatric conditions build on an investigational drug's success in tamping down Tourette syndrome tics.
Read more »
Researchers explore physiological and molecular processes underlying graft healingGrafting has long been a cornerstone in agriculture and forestry, allowing for the propagation of desirable plant traits and improved resistance to environmental challenges. Despite its widespread application, grafting still encounters obstacles, including compatibility issues and difficulties in vascular reconnection between scion and rootstock.
Read more »
Researchers achieve aluminum molecular ring-based rotaxane and polyrotaxaneRotaxanes have garnered interest for their unique structures consisting of mechanically interlocked axles and macrocycles. Numerous organic macrocycles have been employed to construct rotaxanes, including crown ether, cyclobis(paraquat-p-phenylene), calixarene, pillararene, cyclodextrin, and cucurbituril.
Read more »